expiries

The securities have short-term expiries: 65.5% of the portfolio has a residual duration of less than one year. in the sector of lending to small and medium-size companies stood at 207.4 million Euros compared to 220.9 million Euros at the end of December 2010.

Reuters: Press Release 2011

Analysts will focus on the effect of the gradual patent expiries of cancer drug Femara and heart medicine Diovan, which is expected to accelerate later this year.

Novartis Is Expected to Outpace Peers Goran Mijuk 2011

The Swiss group has one of the industry's healthiest pipelines, a fact that should help the group manage the expected sales drop from patent expiries of key drugs that will soon face generic competition.

Novartis Seen Gaining as Merck Scraps MS Drug Goran Mijuk 2011

Although net profit for the three months to the end of June fell to €1.01 billion $1.45 billion from €1.71 billion a year earlier, Sanofi was able to lift sales 0.5% to €8.35 billion from €8.31 billion as the first-time inclusion of Genzyme offset sales losses of €778 million caused by patent expiries.

Sanofi Raises Forecast Goran Mijuk 2011

The sale of Astra Tech to York, Pa.-based Dentsply underscores AstraZeneca's intent to focus on its core medicine development as well as increasing returns to shareholders as it heads into a series of patent expiries on some of its biggest selling medicines—including Nexium, for heartburn and stomach ulcers, and Seroquel for schizophrenia and bipolar disorder.

Astra Sells Dental Unit for $1.8 Billion Margot Patrick 2011

Although the Basel-based company, like its peers, will be hit by currency moves, lower drug prices and patent expiries, Novartis's recent acquisitions and broad product portfolio, which includes over-the-counter drugs and generic medicines, should help it break above the sector.

Novartis Is Expected to Outpace Peers Goran Mijuk 2011

But even as Roche still has a strong pipeline and doesn't face patent expiries like many of its peers, more troubles are looming as Roche risks losing sales from its eye-care treatment Lucentis, which generated more than one billion francs in sales in 2010.

EU Backs Avastin for Breast Cancer Goran Mijuk 2011

Novartis's strong performance will likely contrast starkly with those of its peers, which are expected to suffer from patent expiries, global austerity measures and currency swings.

Novartis Is Expected to Outpace Peers Goran Mijuk 2011

However, the issue is that we've got these big patent expiries in 2012 and 2013, and the shorter-term investors aren't willing to look past that yet, Mr. Chouhan says.

Pharma Edges Toward 'Patent Cliff' Sten Stovall 2011

ZURICH—Switzerland's Novartis AG on Tuesday is expected to post solid second-quarter earnings, outperforming a pharmaceutical sector that otherwise is set to be weighed down by patent expiries and global austerity measures.

Novartis Is Expected to Outpace Peers Goran Mijuk 2011